Changes in Hong Kong stocks | Tong Ren Tang Sinopharm (03613) fell more than 8%, net profit in the first half of the year decreased 15.6% year on year, revenue fell by more than 20%

The Zhitong Finance App learned that Tong Ren Tang Sinopharm (03613) fell by more than 8%. As of press release, it fell 8.38% to HK$5.955, with a turnover of HK$27.5359 million.

According to the news, Tong Ren Tang Sinopharm announced its 2026 interim results. The first half of the year achieved revenue of about HK$602 million, a decrease of 21% over the previous year; the profit attributable to the company's owners was about HK$198 million, a decrease of 15.6% over the previous year. According to the announcement, gross margin rose from 60.8% in the same period last year to 63.9% in the current period, up 3.1% year on year. At the same time, the decline in profit was less than the decline in revenue, indicating that the company's efforts in cost control and product structure optimization continued to bear fruit.

The company said that in the Hong Kong, Macao and mainland markets, the company's strategic logic is clear. The company changed from “price for quantity” to “price control and insurance”, actively tightened distribution channels for its own products, strengthened terminal price control and brand image management, resulting in a 27.8% year-on-year decline in wholesale revenue for its own products. Meanwhile, the retail side showed the opposite trend. The company adopted a strategy of “active shift” rather than passive contraction, and continued to increase the layout of its own product sales network, focusing on expanding the Hong Kong retail market. Hong Kong's retail revenue increased 5% year-on-year during the period.